Lucintel's latest market report analyzed that recombinant protein provides attractive opportunities in pharma & biotechnology companies, academic & research institutes, and diagnostic laboratories. The recombinant protein market is expected to reach $3.8 billion by 2028 with a CAGR of 11.5%. In this market, antibodies is the largest segment by product type, whereas pharma &bioend use industry companies is largest by end use industry.
Download Brochure of this report by clicking on https://www.lucintel.com/recombinant-protein-market.aspx
Based on product type, the recombinant protein market is segmented into hormones, growth factors, enzymes, antibodies, and others. The antibodies segment accounted for the largest share of the market in 2023 and is expected to register the highest CAGR during the forecast period, due to the growing cases of diabetes across the globe.
Browse in-depth TOC on “Recombinant Protein Market”
100 – Figures/Tables
150 – Pages
The Recombinant Protein Market is marked by the presence of several big and small players. Some of the prominent players offering recombinant protein include Abcam, Sino Biological, R&D Systems, GenScript, and Bio-Rad Laboratories.
Request Sample Report:
https://www.lucintel.com/recombinant-protein-market.aspx
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link helpdesk@lucintel.com.
About Lucintel
Lucintel, the premier global management consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, growth consulting, M&A, and due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.